| Disease | OF ALL MAJOR SYMPTOMS OF BPH AND A CONSIDERABLE IMPROVEMENT IN THE QUALITY OF LIFE. THEY REFLECT A GOOD TOLERANCE AND A VERY LOW FREQUENCY OF SIDE EFFECT.
IN 53% IT WAS GOOD, IN 3.5% MODERATE, AND IN 2% MIMINAL OR BAD. ADVERSE REACTIONS WERE REPORTED IN ONE PATIENT (NAUSEA AND FEELING OF FULLNESS). THE RESULTS CONFIRM THE EFFICACY OF NRE IN BPH. THE DATE INDICATES A CLINICALLY RELEVANT REDUCTION
BY THE INVESTIGATORS AS EXCELLENT IN ABOUT 11% OF THE CASES, GOOD IN 59%, MODERATE IN 16%, MINIMAL IN 7%, WITH NO APPARENT EFFECT IN THE REMAINING 6% (NO DATE IN <1%). IN ABOUT 41.5% OF ALL PATIENTS STUDIED, THE GLOBAL TOLERANCE WAS EXCELLENT,
(INITITAL VALUE) TO 1.6 (END OF STUDY). THE MEAN MAXIMAL URINARY FLOW INCREASED BY ABOUT 41% FROM 11.1 ML/SEC, WHILE THE MEAN RESIDULA URINE WAS REDUCED BY ABOUT 41% FROM 72.8 ML TO 42.7 ML. THE GLOBAL EFFICACY OF NRE IN THIS STUDY WAS EVALUATED
FREQUENCY DECREASED BY 49%. THE MEAN IPSS (INTERNATIONAL PROSTATE SYMPTOM SCORE/AMERICAN UROLOGICAL ASSOCIATION) DECREASED BY ABOUT 47% FROM 16.7 (INITIAL VALUE) TO 8.9 (END OF STUDY). THE MEAN QUALITY OF LIFE SCORE IMPROVED BY 50% FROM 3.2
HAD ACCOMPANYING ILLINESSES. THE MEDIAN DOSE WAS 3 CAPSULES PER DAY, WHILE THE MEDIAN DURATION OF TREATMENT WAS 90 DAYS. DATA ANALYSIS WAS PERFORMED USING DESCRIPTIVE AND EXPLORATIVE STATISTICAL METHODS. THE MEAN NOCTURNAL MICTURITION
TREATED WITH SERLESS (1 CAPSULE = 240 MG OF A STANDARDISED EXTRACT OF URTICA RADIX (6.7-8.3:1). THE MEDIUM LENGTH OF SICKNESS WAS 40 WEEKS. UPON RECRUITMENT TO THE PMS STUDY, 47.2% OF THE PATIENTS WERE RECEIVING OTHER BPH MEDICATION, AND 48.2%
THIS THREE MONTH SURVEILLANCE STUDY WAS CONDUCTED TO MONITOR TOLERANCE, ADVERSE REACTIONS AND THERAPEUTIC PROPERTIES OF NRE IN PATIENTS SUFFERING FROM BPH 11-111(VAHLENSIECK). 525 BPH PATIENTS (MEAN AGE=64.1 YEARS, MEAN BMI=26.1 KG/M2) WERE |